Targacept completes patient recruitment for Phase IIb overactive bladder study
US-based biopharmaceutical firm Targacept has completed patient recruitment for its Phase IIb clinical trial of TC-5214 for the treatment for overactive bladder (OAB).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Overactive Bladder | Overactive Bladder Syndrome | Pharmaceuticals | Study